| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| KPRXKiora Pharmaceuticals, Inc. | 8.05M | 2.19 | 2.52 | 22.47% | -38.12% | 100% | 0.00 | |
| KALAKALA BIO, Inc. | 16.74M | 0.60 | -0.09 | -141.11% | -388.29% | 2.62 | ||
| CLSDClearside Biomedical, Inc. | 5.81M | 1.11 | -0.16 | -79.77% | -7.81% | |||
| OTLKOutlook Therapeutics, Inc. | 33.47M | 0.52 | -0.29 | -25.93% | ||||
| ADVMAdverum Biotechnologies, Inc. | 96.26M | 4.36 | -0.66 | -72.22% | -130.93% | -189.84% | 1.30 | |
| IRDOpus Genetics, Inc. | 143.45M | 2.08 | -0.97 | -42.3% | -466.09% | -11.43% | ||
| SKYESkye Bioscience, Inc. | 30.87M | 0.96 | -1.32 | -156.01% | 0.01 | |||
| ALDXAldeyra Therapeutics, Inc. | 265.32M | 4.41 | -4.69 | -87.71% | 0.22 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 2.53M | 2.25M | 1.79M | 1.42M | 1.48M | 773K | 3.9M | 14.7M | 8.95M | 9.5M |
| Revenue Growth % | 0.3% | -0.11% | -0.2% | -0.21% | 0.04% | -0.48% | 4.04% | 2.77% | -0.39% | 0.06% |
| Cost of Goods Sold | 1.11M | 358K | 168K | 302K | 412K | 385K | 1.43M | 728K | 671K | 334K |
| COGS % of Revenue | 0.44% | 0.16% | 0.09% | 0.21% | 0.28% | 0.5% | 0.37% | 0.05% | 0.08% | 0.04% |
| Gross Profit | 1.43M | 1.89M | 1.62M | 1.11M | 1.07M | 388K | 2.47M | 13.97M | 8.27M | 9.16M |
| Gross Margin % | 0.56% | 0.84% | 0.91% | 0.79% | 0.72% | 0.5% | 0.63% | 0.95% | 0.92% | 0.96% |
| Gross Profit Growth % | 0.29% | 0.33% | -0.14% | -0.31% | -0.04% | -0.64% | 5.37% | 4.66% | -0.41% | 0.11% |
| Operating Expenses | 67.24M | 60.86M | 42.28M | 42.11M | 39.94M | 26.84M | 51.68M | 36.49M | 33.01M | 30.64M |
| OpEx % of Revenue | 26.53% | 27.03% | 23.59% | 29.74% | 27.02% | 34.72% | 13.27% | 2.48% | 3.69% | 3.23% |
| Selling, General & Admin | 29.13M | 28.43M | 19.92M | 24.73M | 24.03M | 15.57M | 18.21M | 22.51M | 17.3M | 18.17M |
| SG&A % of Revenue | 11.5% | 12.62% | 11.12% | 17.46% | 16.26% | 20.14% | 4.67% | 1.53% | 1.93% | 1.91% |
| Research & Development | 42.6M | 36.11M | 24.02M | 20.95M | 17.95M | 12.32M | 33.91M | 13.99M | 15.71M | 12.47M |
| R&D % of Revenue | 16.81% | 16.03% | 13.41% | 14.8% | 12.14% | 15.93% | 8.7% | 0.95% | 1.76% | 1.31% |
| Other Operating Expenses | -160K | -403K | 1.45M | -1.31M | -2.04M | -1.05M | -445K | 0 | 0 | 0 |
| Operating Income | -65.81M | -58.97M | -38.9M | -41.8M | -38.88M | -26.45M | -49.21M | -22.52M | -24.73M | -21.48M |
| Operating Margin % | -25.97% | -26.18% | -21.71% | -29.52% | -26.3% | -34.21% | -12.63% | -1.53% | -2.77% | -2.26% |
| Operating Income Growth % | -0.3% | 0.1% | 0.34% | -0.07% | 0.07% | 0.32% | -0.86% | 0.54% | -0.1% | 0.13% |
| EBITDA | -59.48M | -54.21M | -35.61M | -38.52M | -35.88M | -24.41M | -48.34M | -21.79M | -24.04M | -20.87M |
| EBITDA Margin % | -23.47% | -24.07% | -19.87% | -27.2% | -24.27% | -31.58% | -12.41% | -1.48% | -2.69% | -2.2% |
| EBITDA Growth % | -0.41% | 0.09% | 0.34% | -0.08% | 0.07% | 0.32% | -0.98% | 0.55% | -0.1% | 0.13% |
| D&A (Non-Cash Add-back) | 6.33M | 4.76M | 3.3M | 3.27M | 3M | 2.04M | 873K | 727K | 692K | 609K |
| EBIT | -65.81M | -58.97M | -40.66M | -40.99M | -38.88M | -26.45M | -49.21M | -22.52M | -24.73M | -21.48M |
| Net Interest Income | -340K | -747K | -692K | 711K | 1.69M | 1.04M | 2K | 829K | 1.63M | 1.72M |
| Interest Income | 0 | 0 | 0 | 0 | 1.69M | 1.04M | 2K | 829K | 1.63M | 1.72M |
| Interest Expense | 340K | 747K | 692K | 10.87M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 3.16M | 77.59M | 15.61M | -5.33M | 19.64M | 4.52M | 5.94M | -3.29M | 1.45M | 2.9M |
| Pretax Income | -62.65M | 18.62M | -23.29M | -47.13M | -19.23M | -21.92M | -43.27M | -25.81M | -23.28M | -18.58M |
| Pretax Margin % | -24.72% | 8.27% | -13% | -33.28% | -13.01% | -28.36% | -11.11% | -1.76% | -2.6% | -1.96% |
| Income Tax | -4.52M | 0 | 0 | -346K | -7.41M | -1.24M | 0 | 541K | -1.8M | 0 |
| Effective Tax Rate % | 0.75% | 1.8% | 0.86% | 0.98% | 0.61% | 0.94% | 0.99% | 1.02% | 0.92% | 1% |
| Net Income | -46.99M | 33.57M | -19.98M | -45.99M | -11.71M | -20.65M | -43.02M | -26.27M | -21.49M | -18.61M |
| Net Margin % | -18.54% | 14.91% | -11.15% | -32.48% | -7.92% | -26.71% | -11.04% | -1.79% | -2.4% | -1.96% |
| Net Income Growth % | -0.29% | 1.71% | -1.6% | -1.3% | 0.75% | -0.76% | -1.08% | 0.39% | 0.18% | 0.13% |
| Net Income (Continuing) | -58.13M | 18.62M | -23.29M | -46.78M | -11.83M | -20.68M | -43.27M | -26.35M | -21.48M | -18.58M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 49.56M | 12.58M | 1.62M | -1.59M | -1.71M | -1.07M | -1.32M | -1.4M | -1.4M | -1.37M |
| EPS (Diluted) | -0.59 | 0.34 | -0.17 | -0.36 | -0.08 | -0.14 | -0.26 | -0.15 | -0.12 | -0.09 |
| EPS Growth % | -0.07% | 1.58% | -1.5% | -1.12% | 0.77% | -0.72% | -0.86% | 0.42% | 0.2% | 0.23% |
| EPS (Basic) | -0.59 | 0.35 | -0.17 | -0.36 | -0.08 | -0.14 | -0.26 | -0.15 | -0.12 | -0.09 |
| Diluted Shares Outstanding | 79.71M | 99.55M | 114.48M | 126.9M | 145.53M | 150.04M | 164.5M | 169.79M | 172.66M | 200.19M |
| Basic Shares Outstanding | 79.71M | 97.32M | 114.48M | 126.9M | 145.53M | 150.04M | 164.5M | 169.79M | 172.66M | 200.19M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 47.24M | 25.65M | 42.62M | 36.36M | 57.52M | 44M | 111.55M | 60M | 38.44M | 51M |
| Cash & Short-Term Investments | 42.98M | 22.71M | 38.17M | 30.74M | 30.72M | 41.56M | 58.36M | 57.88M | 35.49M | 47.8M |
| Cash Only | 42.23M | 22.09M | 36.84M | 23.59M | 9.5M | 32.59M | 55.74M | 11.36M | 35.44M | 45.79M |
| Short-Term Investments | 753K | 627K | 1.34M | 7.15M | 21.22M | 8.98M | 2.62M | 46.52M | 50K | 2.02M |
| Accounts Receivable | 1.65M | 1.16M | 3.05M | 3.72M | 24.74M | 4K | 50.84M | 297K | 745K | 638K |
| Days Sales Outstanding | 236.95 | 187.52 | 620.42 | 958.64 | 6.11K | 1.89 | 4.76K | 7.37 | 30.4 | 24.52 |
| Inventory | 1K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | 0.33 | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 567K | 0 | 0 | 0 | 2.06M | 0 | 0 | 1.83M | 2.2M | 2.55M |
| Total Non-Current Assets | 47.42M | 116.92M | 130.62M | 65.3M | 67.96M | 63.95M | 63M | 63.66M | 62.58M | 62.22M |
| Property, Plant & Equipment | 7.54M | 5.53M | 5.53M | 5.83M | 8.18M | 5.63M | 4.87M | 5.67M | 4.77M | 4.39M |
| Fixed Asset Turnover | 0.34x | 0.41x | 0.32x | 0.24x | 0.18x | 0.14x | 0.80x | 2.59x | 1.88x | 2.16x |
| Goodwill | 0 | 0 | 0 | 0 | 10.67M | 10.67M | 10.67M | 10.67M | 10.67M | 10.67M |
| Intangible Assets | 33.59M | 10.21M | 6.9M | 3.13M | 48.25M | 47.03M | 46.82M | 46.69M | 46.56M | 46.54M |
| Long-Term Investments | 4.67M | 100.04M | 117.17M | 33.73M | 100K | 0 | 0 | 581K | 0 | 0 |
| Other Non-Current Assets | 1.3M | 1.03M | 1.02M | 505K | 764K | 616K | 630K | 627K | 577K | 614K |
| Total Assets | 94.66M | 142.57M | 173.24M | 101.66M | 125.48M | 107.95M | 174.54M | 123.66M | 101.02M | 113.22M |
| Asset Turnover | 0.03x | 0.02x | 0.01x | 0.01x | 0.01x | 0.01x | 0.02x | 0.12x | 0.09x | 0.08x |
| Asset Growth % | 0.26% | 0.51% | 0.22% | -0.41% | 0.23% | -0.14% | 0.62% | -0.29% | -0.18% | 0.12% |
| Total Current Liabilities | 12.46M | 8.85M | 6.88M | 6.81M | 6.49M | 7.77M | 47.12M | 18.98M | 17.96M | 13.98M |
| Accounts Payable | 2.8M | 1.59M | 938K | 2.36M | 2.43M | 2.61M | 3.54M | 2.39M | 2.05M | 1.17M |
| Days Payables Outstanding | 922.56 | 1.62K | 2.04K | 2.85K | 2.15K | 2.48K | 906.87 | 1.2K | 1.12K | 1.28K |
| Short-Term Debt | 95K | 932K | 152K | 70K | 1.22M | 523K | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 1000K | 572K | 797K | 42K | 45K | 193K | 1000K | 1000K | 1000K | 1000K |
| Other Current Liabilities | 3.38M | 3.65M | 2.5M | 1.65M | 1.25M | 1.97M | 2.54M | 3.83M | 3.12M | 0 |
| Current Ratio | 3.79x | 2.90x | 6.20x | 5.34x | 8.86x | 5.66x | 2.37x | 3.16x | 2.14x | 3.65x |
| Quick Ratio | 3.79x | 2.90x | 6.20x | 5.34x | 8.86x | 5.66x | 2.37x | 3.16x | 2.14x | 3.65x |
| Cash Conversion Cycle | -685.28 | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 5.75M | 3.21M | 2.1M | 2.6M | 7.74M | 5.05M | 36.53M | 32.75M | 21.04M | 22.23M |
| Long-Term Debt | 544K | 1.15M | 18K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 4.43M | 1.7M | 1.15M | 1.96M | 3.94M | 2.54M | 1.97M | 2.94M | 2.07M | 1.36M |
| Deferred Tax Liabilities | 158K | 50K | 0 | 0 | 3.31M | 2.08M | 2.08M | 2.08M | 273K | 273K |
| Other Non-Current Liabilities | 166K | 58K | 930K | 644K | 277K | 437K | 30K | 2K | 0 | 6.16M |
| Total Liabilities | 18.21M | 12.06M | 8.98M | 9.41M | 14.23M | 12.82M | 83.65M | 51.73M | 39M | 36.21M |
| Total Debt | 5.1M | 3.98M | 1.53M | 2.27M | 5.17M | 3.83M | 2.8M | 3.9M | 2.95M | 2.51M |
| Net Debt | -37.13M | -18.11M | -35.3M | -21.32M | -4.33M | -28.76M | -52.94M | -7.46M | -32.49M | -43.27M |
| Debt / Equity | 0.07x | 0.03x | 0.01x | 0.02x | 0.05x | 0.04x | 0.03x | 0.05x | 0.05x | 0.03x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -193.56x | -78.94x | -56.22x | -3.84x | - | - | - | - | - | - |
| Total Equity | 76.45M | 130.51M | 164.26M | 92.25M | 111.25M | 95.13M | 90.9M | 71.94M | 62.02M | 77.01M |
| Equity Growth % | 0.22% | 0.71% | 0.26% | -0.44% | 0.21% | -0.14% | -0.04% | -0.21% | -0.14% | 0.24% |
| Book Value per Share | 0.96 | 1.31 | 1.43 | 0.73 | 0.76 | 0.63 | 0.55 | 0.42 | 0.36 | 0.38 |
| Total Shareholders' Equity | 26.89M | 117.93M | 162.64M | 93.84M | 112.96M | 96.2M | 92.22M | 73.34M | 63.42M | 78.38M |
| Common Stock | 274.34M | 317.88M | 378.49M | 354.27M | 387.06M | 393.94M | 434.53M | 440.28M | 451.34M | 484.72M |
| Retained Earnings | -229.18M | -196.32M | -216.3M | -261.86M | -273.42M | -294.08M | -337.1M | -363.37M | -384.86M | -403.46M |
| Treasury Stock | -18.03M | -2.89M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -237K | -738K | 451K | 1.43M | -681K | -3.67M | -5.21M | -3.57M | -3.07M | -2.88M |
| Minority Interest | 49.56M | 12.58M | 1.62M | -1.59M | -1.71M | -1.07M | -1.32M | -1.4M | -1.4M | -1.37M |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -44.54M | -42.33M | -30.52M | -30.88M | -31.95M | -19.75M | -23.56M | 1.06M | -28.57M | -23.09M |
| Operating CF Margin % | -17.58% | -18.79% | -17.03% | -21.81% | -21.62% | -25.55% | -6.05% | 0.07% | -3.19% | -2.43% |
| Operating CF Growth % | -0.15% | 0.05% | 0.28% | -0.01% | -0.03% | 0.38% | -0.19% | 1.04% | -27.97% | 0.19% |
| Net Income | -58.13M | 18.62M | -23.29M | -46.78M | -11.83M | -20.68M | -43.27M | -26.35M | -21.49M | -18.61M |
| Depreciation & Amortization | 6.33M | 4.76M | 3.3M | 3.27M | 3M | 2.04M | 873K | 727K | 692K | 609K |
| Stock-Based Compensation | 11.05M | 7.95M | 3.93M | 5.4M | 3.58M | 2.23M | 3.52M | 4.29M | 4.64M | 5.08M |
| Deferred Taxes | -4.52M | -4.52M | -17.57M | -346K | -7.41M | -1.24M | -6M | 0 | -1.8M | 0 |
| Other Non-Cash Items | -2.58M | -68.4M | 640K | 6.93M | -17.34M | -3.47M | 202K | 3.73M | 195K | -1.4M |
| Working Capital Changes | 3.31M | -741K | 2.48M | 638K | -1.96M | 1.37M | 21.11M | 18.67M | -10.8M | -8.77M |
| Change in Receivables | -248K | -39K | -172K | 46K | 467K | 287K | -857K | 50.31M | -446K | 106K |
| Change in Inventory | -75K | -75K | 1.3M | 122K | 2.88M | -308K | -72K | 0 | 0 | 0 |
| Change in Payables | 1.67M | 12K | 1.3M | 1.1M | -2.88M | 308K | 21.64M | -18.7M | -2.29M | -1.68M |
| Cash from Investing | -7.44M | -10.89M | -10.22M | 11.82M | 16.96M | 13.04M | 9.74M | -46.16M | 46.45M | -2.31M |
| Capital Expenditures | -5.33M | -2.53M | -1.33M | -3.29M | -440K | -64K | -354K | -413K | -674K | -565K |
| CapEx % of Revenue | 2.1% | 1.12% | 0.74% | 2.32% | 0.3% | 0.08% | 0.09% | 0.03% | 0.08% | 0.06% |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -859K | 13K | 188K | -8K | 65K | 41K | 14K | -45.75M | 0 | 0 |
| Cash from Financing | 64.78M | 32.78M | 55.39M | 5.77M | 617K | 29.86M | 36.93M | 1.63M | 6.42M | 35.86M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | -34.41M | -182K | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 15.47M | 324K | -3.57M | 35.77M | 1.01M | 24.79M | 6.14M | 1.53M | -37K | 58K |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -49.88M | -44.85M | -31.84M | -34.17M | -32.39M | -19.82M | -23.91M | 646K | -29.24M | -23.66M |
| FCF Margin % | -19.68% | -19.92% | -17.77% | -24.13% | -21.91% | -25.64% | -6.14% | 0.04% | -3.27% | -2.49% |
| FCF Growth % | -0.27% | 0.1% | 0.29% | -0.07% | 0.05% | 0.39% | -0.21% | 1.03% | -46.26% | 0.19% |
| FCF per Share | -0.63 | -0.45 | -0.28 | -0.27 | -0.22 | -0.13 | -0.15 | 0.00 | -0.17 | -0.12 |
| FCF Conversion (FCF/Net Income) | 0.95x | -1.26x | 1.53x | 0.67x | 2.73x | 0.96x | 0.55x | -0.04x | 1.33x | 1.24x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -67.53% | 32.44% | -13.55% | -35.86% | -11.51% | -20.01% | -46.25% | -32.27% | -32.08% | -26.77% |
| Return on Invested Capital (ROIC) | -135.07% | -58.3% | -24.18% | -31.36% | -32.79% | -22.89% | -70.76% | -32.98% | -39.46% | -50.92% |
| Gross Margin | 56.31% | 84.1% | 90.63% | 78.67% | 72.12% | 50.19% | 63.4% | 95.05% | 92.5% | 96.48% |
| Net Margin | -1854.42% | 1490.76% | -1114.73% | -3247.88% | -792.22% | -2671.28% | -1104.18% | -178.69% | -240.2% | -195.9% |
| Debt / Equity | 0.07x | 0.03x | 0.01x | 0.02x | 0.05x | 0.04x | 0.03x | 0.05x | 0.05x | 0.03x |
| Interest Coverage | -193.56x | -78.94x | -56.22x | -3.84x | - | - | - | - | - | - |
| FCF Conversion | 0.95x | -1.26x | 1.53x | 0.67x | 2.73x | 0.96x | 0.55x | -0.04x | 1.33x | 1.24x |
| Revenue Growth | 30.19% | -11.13% | -20.43% | -20.98% | 4.38% | -47.7% | 404.01% | 277.39% | -39.16% | 6.19% |
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Collaboration Revenues | - | - | - | - | 13.37M | 7.59M | 8.15M |
| Collaboration Revenues Growth | - | - | - | - | - | -43.23% | 7.39% |
| Royalties | - | - | - | - | 1.34M | - | - |
| Royalties Growth | - | - | - | - | - | - | - |
| Royalty | - | - | - | 2.78M | - | - | - |
| Royalty Growth | - | - | - | - | - | - | - |
| Reimbursements Cost Sharing Payments | - | - | - | 545K | - | - | - |
| Reimbursements Cost Sharing Payments Growth | - | - | - | - | - | - | - |
| Upfront License Fees | - | - | - | 452K | - | - | - |
| Upfront License Fees Growth | - | - | - | - | - | - | - |
| Event Based Development Milestones | - | - | - | 123K | - | - | - |
| Event Based Development Milestones Growth | - | - | - | - | - | - | - |
| Grant | - | - | 1.05M | - | - | - | - |
| Grant Growth | - | - | - | - | - | - | - |
| Royalties From Product Sales and License Fees | 392K | 1.22M | 773K | - | - | - | - |
| Royalties From Product Sales and License Fees Growth | - | 211.48% | -36.69% | - | - | - | - |
| Grant Revenue | 3.57M | 2.04M | - | - | - | - | - |
| Grant Revenue Growth | - | -42.97% | - | - | - | - | - |
| Sale of Research Products and Services | 333K | 257K | - | - | - | - | - |
| Sale of Research Products and Services Growth | - | -22.82% | - | - | - | - | - |
| Subscription and Advertisement Revenues | 691K | - | - | - | - | - | - |
| Subscription and Advertisement Revenues Growth | - | - | - | - | - | - | - |
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| UNITED STATES | - | - | 1.16M | 3.9M | 14.7M | - | - |
| UNITED STATES Growth | - | - | - | 235.78% | 277.48% | - | - |
| Foreign | 3.18M | 1.42M | 666K | 446K | - | - | - |
| Foreign Growth | - | -55.31% | -53.20% | -33.03% | - | - | - |
| United States | 1.8M | 2.09M | - | - | - | - | - |
| United States Growth | - | 15.96% | - | - | - | - | - |
Lineage Cell Therapeutics, Inc. (LCTX) reported $10.8M in revenue for fiscal year 2024. This represents a 148% increase from $4.4M in 2011.
Lineage Cell Therapeutics, Inc. (LCTX) grew revenue by 6.2% over the past year. This is steady growth.
Lineage Cell Therapeutics, Inc. (LCTX) reported a net loss of $67.7M for fiscal year 2024.
Lineage Cell Therapeutics, Inc. (LCTX) has a return on equity (ROE) of -26.8%. Negative ROE indicates the company is unprofitable.
Lineage Cell Therapeutics, Inc. (LCTX) had negative free cash flow of $20.9M in fiscal year 2024, likely due to heavy capital investments.